


Trends in annual price for disease-modifying therapies for multiple sclerosis; 1997 to 2021



Drug	5 Year Change*	1 Year Change**	Annual Price 2021
Self-administered injections			
Betaseron	35.6%	3.0%	\$106,401
Avonex	30.0%	2.0%	\$93,672
Rebif	48.3%	11.3%	\$115,359
Extavia	23.7%	0.0%	\$81,079
Plegridy	30.0%	2.0%	\$93,672
Kesimpta			\$83,000
Glatiramer Acetate			
Copaxone 20	7.9%	0.0%	\$86,554
Copaxone 40	7.9%	0.0%	\$75,816
Glatopa	-71.1%	0.0%	\$18,250
Glatopa 40		0.0%	\$19,500
Glat Acet (Mylan)		0.0%	\$23,725
Glat Acet 40 (Mylan)		0.0%	\$25,350
Oral DMTs			
Gilenya	41.6%	5.0%	\$110,660
Aubagio	31.8%	5.1%	\$98,054
Tecfidera	37.6%	0.0%	\$100,690
Mayzent		5.0%	\$98,036
Mavenclad		12.4%	\$120,742
Vumerity		4.0%	\$91,520
Zeposia		4.5%	\$89,870
Bafiertam			\$69,770
Dimethyl fumarate***			\$3,650
Infusions			
Tysabri	35.2%	8.9%	\$97,032
Lemtrada	27.9%	4.8%	\$84,168
Ocrevus		3.0%	\$66,950

Notes: Annual price estimated from wholesale acquisition costs (First Databank)
Market entrance date in parenthesis

Dashed line is projected annual price of Betaseron assuming only inflationary increases in price (CPI)

Lemtrada is based on four 12 mg vials (Package insert dosing: 12 mg/day (5 vials) for five consecutive days in first year; 12 mg/day (3 vials) for three days in year 2);

*2016 to 2021 (February); **2020 to 2021 (February); ***lowest price dimethyl fumarate reported

Updated 2.18.2021 (Data through February 2021)

